	=
S	Ē
/1	
9	Ξ
01	Ξ
_	=

Page 1 of 2 Docket No.: V-259.00 UTILITY PATENT Title: Method of Isolation and Purification of Trypsin APPLICATION TRANSMITTAL From Pronase And Use Thereof Express Mail Label No.: (n/a) (Under 37 C.F.R. §1.53(b)) ADDRESS TO: Assistant Commissioner for Patents **APPLICATION ELEMENTS Box Patent Application** Washington, D.C. 20231 INVENTORS: Artur Mitterer Christa Tauer Manfred Reiter Wolfgang Mundt Copies of IDS Fee Transmittal Form (Submit an original, and a duplicate Information Disclosure 10. 1. Citations Statement (IDS)/PTO-1449 for fee processing) Preliminary Amendment **[Total Pages**] 11. 2. Specification] Return Receipt Postcard (MPEP 503) **ITotal Pages** 12. Drawing(s) (35 USC §113)] 3. (Figs. 1-4) Small Entity Statement(s) 13. [Total Pages 1 4 Signed Declaration Certified Copy of Priority Documents (s) 14. Newly executed (original or copy) a. Cancel in the application original claims Copy from a prior application (37 CFR §1.63(d)) 15a. before calculating the filing fee (Note Box 5 below) Amend the specification by inserting before the first line the 15b. DELETION OF INVENTOR(S) -This is a ___ Continuation, sentence: ___ Continuation-in-part, of application Divisional, Signed statement attached deleting invento filed named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b) I hereby verify that the attached papers are a true copy of the 15c. latest inventor-signed prior application, including a copy of the oath Incorporation By Reference (useable if Box 4b is checked.) or declaration showing the original signature or an indication it was The entire disclosure of the prior application, signed. I hereby verify that the papers are a true copy of the latest from which a copy of the oath or declaration is supplied signed prior application number ___ . filed under Box 4b, is considered as being part of the aAnd further that all statements made herein of my own knowledge disclosure of the accompanying application and is are true; and further that these statements were made with the hereby incorporated by reference therein. knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false Nucleotide and/or Amino Acid Sequence Submission 6 statements may jeopardize the validity of the application or any Patent issuing thereon. Computer Readable Copy Paper Copy (identical to computer copy) h. Statement Verifiving identify of above copies c Assignment Papers (cover sheet & document(s)) Other: 15d. Power of 37 CFR §3.73(b) Statement 8. Attorney **English Translation Document** 9. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: Divisional Continuation Continuation-in-part (CIP) of prior application No.: _

UTILITY PATENT APPLICATION TRANSMITTAL

Docket No.: V-259.00

Page 2 of 2

Title: Method of Isolation and Purification of Trypsin

From Pronase And Use Thereof

(Under 37 C.F.R. §1.53(b))

Express Mail Label No.: (n/a)

	(Under 37 C.F.R. §1.53(b))	Express Mail Lai	Del No (II/a)		
CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS	
	TOTAL CLAIMS (37 CFR 1.16(b))	25-20 =	5	X \$ 18 =	\$90.00	
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	2-3 =	0	X \$ 84 =	\$ 0	
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 280 =	\$0	
April 18				BASIC FEE (37 CFR §1.16(a))	\$740.00	
				TOTAL =	\$830.00	
For this purpose petition for an a	ng the pendency of the apse, pursuant to 37 CFR § appropriate extension of times required under 37 CFR §1	1.136(a)(3) pleasome if a petition for .16	e incorporate the	above authorization in	to any future reply as a	
	ees required under 37 CFR §1		NT, ATTORNEY, O	R AGENT		
NAME	C. Joseph Faraci, Reg. No. 32,350					
SIGNATURE	Coplain					
DATE	December 6, 2001					
		CORRESPO	NDENCE ADDRESS			
	Tele	P.O.	thcare Corporation Box 15210 alifornia 92614 6827 Fax: (949) 474- 6 330		
I here Label No. 20231 on	by certify that the above-idenin an envelope a	tified document is b	tent Application, Ass		atents, Washington, D.C.	